SCHEMBL19857549

SCHEMBL19857549

COn1ccc2c(C(N)=O)cccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 2/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40
TUBB2B Q9BVA1 1/20 0.40
TUBB1 Q9H4B7 1/20 0.40
GAA P10253 1/20 0.40
PARP1 P09874 2/20 0.39
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11218801 0.84 NR4A2 (0.50) KDM4EALDH1A1GAANR4A2L3MBTL1
SCHEMBL19691124 0.79 NR4A2 (0.47) KDM4EALDH1A1GAANR4A2L3MBTL1
SCHEMBL4109141 0.78 TUBB4A (0.52) KDM4EALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL1794843 0.76 KDM4E (0.44) KDM4EALDH1A1GAAPARP1L3MBTL1
SCHEMBL14917590 0.74 EZH2 (0.48) KDM4EALDH1A1GAAPARP1L3MBTL1
SCHEMBL4955608 0.74 ALDH1A1 (0.39) KDM4EALDH1A1PARP1NR4A2MAPT
SCHEMBL4949214 0.74 HTR2C (0.46) KDM4EALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL19857564 0.72 PARP1 (0.46) KDM4EPARP1L3MBTL1PKN1PKN2
SCHEMBL30779329 0.71 DHFR (0.42) KDM4EALDH1A1GAAPARP1RPS6KB1
SCHEMBL11217145 0.71 NR4A2 (0.47) KDM4EALDH1A1GAANR4A2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex CLEAVE BIOSCIENCES, INC. (US) 2019-01-08 US disclosed
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX CLEAVE BIOSCIENCES, INC. 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex WDR77, POP1, PSMG3 KDM4E 3475/4885ALDH1A1 3652/4885TUBB4A 1218/4885
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX WDR77, POP1, PSMG3 KDM4E 3452/4885ALDH1A1 3662/4885TUBB4A 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.